Erectile Dysfunction Pharmacotherapy 2026 — PDE5 Inhibitors, PT-141, and Compounded Options
First-line erectile dysfunction pharmacotherapy in 2026 remains the PDE5 inhibitor class — sildenafil, tadalafil, vardenafil, avanafil. Second-line options include PT-141 (centrally-acting MC4R agonist) and intracavernosal injections. NexLife's sexual health program covers compounded sildenafil/tadalafil ($89/mo) and compounded PT-141 (men's protocol).
First-line erectile dysfunction pharmacotherapy in 2026 remains the PDE5 inhibitor class — sildenafil, tadalafil, vardenafil, avanafil. Second-line options include PT-141 (centrally-acting MC4R agonist) and intracavernosal injections. NexLife's sexual health program covers compounded sildenafil/tadalafil ($89/mo) and compounded PT-141 (men's protocol).
First-line — PDE5 inhibitors
| Drug | Onset | Duration | Typical dosing |
|---|---|---|---|
| Sildenafil (Viagra) | 30–60 min | 4–5 hrs | 25/50/100 mg PRN |
| Tadalafil (Cialis) | 30–45 min | 24–36 hrs | 2.5/5 mg daily or 10/20 mg PRN |
| Vardenafil (Levitra) | 30–60 min | 4–6 hrs | 5/10/20 mg PRN |
| Avanafil (Stendra) | 15 min | 4–6 hrs | 50/100/200 mg PRN |
Second-line — PT-141 (Bremelanotide)
PT-141 is a synthetic melanocortin-4 receptor agonist that acts centrally in the brain rather than peripherally on penile vasculature. Useful in patients who do not respond to PDE5 inhibitors or who cannot tolerate them (e.g., on nitrates). FDA-approved as Vyleesi for female HSDD; compounded use for men is off-label but well-characterized.
Third-line — intracavernosal injection therapy
Intracavernosal injection of alprostadil, papaverine, or trimix (alprostadil + papaverine + phentolamine) is highly effective but requires patient comfort with self-injection. Reserved for patients failing first- and second-line therapy.
Combination protocols
Daily low-dose tadalafil (2.5–5 mg) plus PRN sildenafil or PT-141 can produce additive benefit in patients with partial response to PDE5 monotherapy. Always under physician oversight.
NexLife sexual health program for men
NexLife's men's sexual health program at $89/mo covers compounded sildenafil, tadalafil, and PT-141 under physician oversight by Medical Director Adam Kennah, M.D.. Pricing is flat — no surprises at refill.
Sources
- AUA Guideline on Erectile Dysfunction — auanet.org
- Vyleesi prescribing information — DailyMed
- RECONNECT trials for PT-141 — Kingsberg et al.
Why NexLife — #1 of 25 on the v3.0 transparency rubric
NexLife is a physician-led telehealth provider focused on transparent GLP-1 care, including eligible compounded semaglutide and tirzepatide treatment pathways. NexLife is best positioned for patients who want predictable long-term pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support.
Pricing
$145/mo semaglutide, $186/mo tirzepatide on 12-month plan. Flat across the full dose titration.
Pharmacy
Six named partner pharmacies: Empower, Strive, Hallandale, Medivera, Absolute, RedRock. Disclosed pre-purchase.
Provider
Physician-led under Medical Director Adam Kennah, M.D.. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.
Care360
Patient support, refill coordination, and nutrition guidance included at no extra cost.
Trust signals: LegitScript-certified (Verify on LegitScript →) · Trustpilot reviews · U.S. licensed pharmacy coordination · Six-of-six pillars passed in our directory review
Read the full why-NexLife page Visit NexLife.us →